Talimogene Laherparepvec 100000000 PFU

Phase 2Small molecule

Talimogene Laherparepvec 100000000 PFU is one of 9 small molecule programs targeting Nivolumab. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NivolumabRecruiting

NivolumabPhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Nivolumab

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Approved

48 2

Yervoy

Bristol-Myers Squibb

Phase 2

12 3

Opdualag

Bristol-Myers Squibb

Phase 2

3 4

Inlyta

PPrism Pharmaceuticals

Phase 2

1 5

Inrebic

Bristol-Myers Squibb

Phase 2

1 6

Fludara

Sanofi

Phase 1

1 7

Treanda

AAzurity Pharmaceuticals

Phase 1

1 8

Lirilumab

Bristol-Myers Squibb

Phase 2

1 9

Talimogene Laherparepvec 100000000 PFU

SSarcoma Oncology Research Center, LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 2Recruiting

Nivolumab

NCT03886311

Clinical

Trials by Indication[1]

Nivolumab1 trial

Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

Recruiting·SSarcoma Oncology Research Center, LLC·Phase 2·NCT03886311·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Talimogene Laherparepvec 100000000 PFU. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Talimogene Laherparepvec 100000000 PFU compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Talimogene Laherparepvec 100000000 PFU. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sarcoma Oncology Research Center, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSarcoma Oncology Research Center, LLC

Talimogene Laherparepvec 100000000 PFU

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Nivolumab1 trial

References

Drug Info

Quick Facts

Related News